Federal nutritionists within the U. S buy protonix online. are investigating whether or not the blood thinner Plavix our planets second-best-selling drug, employed by millions to reduce the risk of heart attack and stroke may be less capable in some patients.
The Fda said it is reviewing reports that you heartburn medications can neutralize the key benefits of Plavix.
The agency said Monday additionally it is investigating whether patients from certain genetic backgrounds cant reap the drugs benefits.
In both cases, the FDA said patients can have trouble metabolizing Plavix, reducing being able to prevent deadly thrombus.
Plavix had global sales of $7. 3 billion US in 2007. The medication is sold by Bristol-Myers Squibb Co. and Sanofi-Aventis SA and possesses been prescribed to over 90 million patients around the world.
In November, researchers found that taking Plavix with popular prescription heartburn drugs like AstraZeneca PLCs Nexium significantly increased patients likelihood of undergoing treatment in hospital for just a cardiac event, stroke or heart problems.
The researchers suggested the heartburn drugs might obstruct a liver enzyme needed to metabolize Plavix.
However, some heart experts were skeptical with the findings. They noted that patients taking heartburn drugs may have already got health conditions that skew their risk for stroke as well as other problems.
Doctors prescribe so-called proton pump inhibitor drugs to manage heartburn, during which painful stomach acids return in the esophagus.
Because Plavix, known generically as clopidogrel, can upset the stomach, it is usually prescribed using the acid-blocking drugs, such as Wyeths Protonix.
Other heartburn optionsFDA said it is essential to determine that this drugs interact because "decreases inside effectiveness of clopidogrel could possibly be avoided, to some extent, by employing other drugs that wont interfere with its metabolism. "
FDA said theres no evidence how the "H2 blocker" family of heartburn drugs counteract Plavix. Those drugs include Johnson & Johnsons Pepcid, Boehringer Ingelheims Zantac and GlaxoSmithKlines Tagamet HB.
Sanofi-Aventis and Bristol-Myers Squibb said they are conducting studies of whether genes or heartburn drugs can restrict Plavix.
"Individuals usually do not all interact to the identical degree to your specific drug," said Sanofi spokeswoman Elizabeth Baxter. "Many research is currently ongoing, including studies of clopidogrel, for more information on what is liable for this phenomenon. "
The studies will need almost a year to perform, based on the FDA, which said it will issue recommendations after reviewing them.
Until details is obtainable, the FDA says patients should continue taking Plavix. However, doctors must be cautious when prescribing the heartburn drugs to patients already taking Plavix.
In general, the FDA has begun notifying the population earlier about possible issues of safety involving drugs.
The policy change came following agency was criticized for acting too slowly on information regarding medicines which were later taken off the marketplace for safety reasons.
The Canadian Press, 2009
.
